| Garlanda Cecilia |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Greco Luana |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Jaillon Sebastien |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mantovani Alberto |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mapelli Sarah |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Marchesi Federica |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Pasqualini Fabio |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Abdurahim Saeed |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Alberici Federico |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Anstadt Robert |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Antonucci Luca |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Ariceta Gema |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Armelloni Silvia |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Armstrong Lye |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Assanelli Andrea |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Atanasiu Doina |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Banda Nirmal |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Barbarossa Annalisa |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Barr William |
Sex Chromosome Regulation of Complement System Activity: Evidence for Post-Transcriptional Control of C3 and C4 Levels
|
| Bassanese Giulia |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Battaglino Cedric |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Beeckmans Hanne |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Benigni Ariela |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Berthenet Kevin |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Blagojevic Aleksandra |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Blom Anna |
Complement factor H is a novel ligand for the inducible T cell co-stimulator (ICOS) and promotes survival or regulatory T cells in the glioma microenvironment
|
| Bodnaruk Iryna |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Bomback Andrew |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Bongoni Anjan |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Bos Saskia |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Bosàkovà Veronika |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Boudhabhay Idris |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
Cell-intrinsic complement in endothelium
|
| Bouyain Samuel |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Bracke Laura |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Brekke Ole- |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Brenner Michael |
Granzyme K Activates the Entire Complement Cascade
Granzyme K-driven complement activation
|
| Bresin Elena |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
|
| Bright Matthew |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
|
| Butler Samuel |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Cairns Tina |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Cappoli Andrea |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Carriero Roberta |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Castellano Giuseppe |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Catalano Marco |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Cedzyński Maciej |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Celik Selvi |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Cerniauskas Edvinas |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Ceulemans Laurens |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Chang Nan-Shan |
Serum complement internalization is needed for UV-mediated nuclear bubbling cell death
|
| Chen Xi |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Ciceri Fabio |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Cicia Donatella |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Claes Sandra Claes |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Cohen Gary |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Colombo Federico |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Connolly E. Sander |
Complement Activity in Emboli Retrieved During Thrombectomy for Ischemic Stroke
|
| Cowan Peter |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Curtin Karen |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Czerwiński Marcin |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Czyszczoń Paula |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Dabrowska-Schlepp Paulina |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Dambra Monica |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| De Castro Deus Marina |
Cell-intrinsic complement in endothelium
|
| De winter Karen |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Delahaye Tim |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Delmas Yahsou |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Deschatelets Pascal |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Dettner Alina |
The involvement of complement system in immune mediated platelet clearance processes
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
|
| Developement team ARDA |
The story of empasiprubart (ARGX-117), a long acting inhibitory C2 antibody, from bench to MMN patients
|
| Dixon Bradley |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Doherty Mary |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Donadelli Roberta |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Donado Carlos |
Granzyme K Activates the Entire Complement Cascade
|
| Duan Huiquan |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Eikrem David |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
|
| Eitel Ingo |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Emblem Åse |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Emma Francesco |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Fakhouri Fadi |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Filip-Psurska Beata |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Fisicaro Nella |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Fleckenstein Monika |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Fontana Juan |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Friščić Jasna |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Fromell Karin |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
|
| Fung Jenny |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Gaboriaud Christine |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Gadzinowski Mariusz |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Gajek Gabriela |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Gál Péter |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Gale Daniel |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Garcia Brandon |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Gargiulo Antonio |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Garlanda Cecilia |
Humoral Innate Immunity and Acute Phase Proteins in COVID-19
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Geisbrecht Brian |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Geisler Sven |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Ghaboosh Hiba |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Ghebrehiwet Berhane |
The C1q and gC1qR proteins as therapeutic targets in cancer
|
| Giannini Carolina |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Goicoechea de Jorge Elena |
Complement dysregulation behind the scenes in ANCA-associated vasculitis
|
| Gragoll Carolin |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Greenbaum Larry |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Grizzi Fabio |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Grønli Renathe |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Gudino Victoria |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Guse Kirsten |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Guzzo Isabella |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Hack Erik |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Hageman Gregory |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Hajishengallis George |
Maladaptive trained immunity and chronic inflammation
|
| Hallam Dean |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Han Seung Hyeok |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Hanack Christina |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Harris Claire |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Harvey Friedman |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Haut Nolwenn |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Höchsmann Britta |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Hoffmann Markus |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Holers V |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Hook Lauren |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Hoxha Elion |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Huber-Lang Markus |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
The involvement of complement system in immune mediated platelet clearance processes
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
|
| Ikehata Masami |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Imanifard Zahra |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
|
| Isbel Nicole |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Iuzzolino Lucia |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Jarych Dariusz |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Jin Xin |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Joakimsen Ingrid |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Jonsson A. Helena |
Granzyme K Activates the Entire Complement Cascade
|
| Julianisya Alana |
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Kaes Janne |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Karlsen Bård |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Kasperkiewicz Katarzyna |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Kavanagh David |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Ke BoJun |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| King Ben |
Complement and Diabetes in rodent models: complement controls metabolism, and metabolism controls complement
|
| Kiss Bence |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Klint Cecilia |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Kocsis Andrea |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Koehl Joerg |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Köhl Jörg |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
|
| Kolev Martin |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Kor Viktor |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Kortleven Pheline |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Kozma Viktoria |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Kulak Klaudia |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Kurzawa Marzena |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Lako Majlinda |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Lambris John |
Therapeutic complement modulation at the forefront of novel immunotherapies: Misconceptions, myths, and novel insights
The involvement of complement system in immune mediated platelet clearance processes
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Lee John |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Li Li |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Licht Christoph |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Lill Markus |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Link-Lenczowski Paweł |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Liu Jin |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| López Lázaro Luis |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Łukasiewicz Jolanta |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Maciejewska Anna |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Magrini Elena |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Malik Kamil |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Mannes Marco |
The involvement of complement system in immune mediated platelet clearance processes
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Marasà Maddalena |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Maritati Federica |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Martynowski Dariusz |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Mastaglio Sara |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Mastellos Dimitris |
TBA - Mastellos
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Mastrangelo Antonio |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Matteoli Gianluca |
Targeting Fibroblast-Derived C3: A Potential Therapeutic Strategy to Halt Chronic Inflammation in IBD.
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Mattinzoli Deborah |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| McRae Jennifer |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Meyer Florian |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Mikołajczyk Krzysztof |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Mizuno Masashi |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Mohler Jennifer |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Mollnes Tom |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Montagner Sara |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Morgan B. Paul |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
Targeting complement in brain diseases.
|
| Moro Marc |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Muntz Fenella |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Nagy Zoltán |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Németh Bálint |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Nester Carla |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Neves de Holanda Maria Izabel |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Nguyen Van Dien |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
|
| Nilsson Bo |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Nilsson Ekdahl Kristina |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
|
| Noris Marina |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Novysedlak Rene |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Olcina Monica |
Selective pressures driving altered complement protein expression in the tumour microenvironment
|
| Padoa Sofia |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Pál Gábor |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Pappas Chris |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Penati Francesca |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Pettersen Kristin |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Pezone Giovanni |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Pickering Matthew |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Pinheiro Sofia |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Pio Ruben |
Targeting complement in immunosuppressive tumor microenvironments
|
| Piras Rossella |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
|
| Podestà Manuel |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Poppelaars Felix |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Pouw Richard |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Quintana Porras Luis Fernando |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Rabbani Said |
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Ranson Neil |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Ratajczak Mariusz |
The different responsiveness of C3- and C5-deficient murine BM cells to oxidative stress explains why C3 deficiency, in contrast to C5 deficiency, correlates with better pharmacological mobilization and engraftment of hematopoietic stem cells.
|
| Rawish Elias |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Read Austin |
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Redissi Alaeddine |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
|
| Remuzzi Giuseppe |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Rezola Artero Mikel |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
|
| Richards Burt |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Ricklin Daniel |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Risitano Antonio Maria |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Rodo Jordi |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Rojas Rechy Moises |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Rossi Véronique |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Roumenina Lubka |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
Complement in Sickle Cell Disease
Cell-intrinsic complement in endothelium
|
| Ruggeri Annalisa |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Rumano Merita, |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Rusack Timo |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Rüthemann Peter |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Sahu Arvind |
Viral teachings on complement regulation
|
| Salas Azucena |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Salvaris Evelyn |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Santhosh Sneha |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Savukoski Susa |
The involvement of complement system in immune mediated platelet clearance processes
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
|
| Saw Wan Ting |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Schaefer Franz |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Schmidt Christoph |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
|
| Schmitz-Valckenberg Steffen |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Schneider Michael |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Schols Dominique |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Schrezenmeier Hubert |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Schubart Anna |
Iptacopan (Fabhalta) for the treatment of complement-mediated diseases
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
|
| Schwaeble Wilhelm |
Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway
|
| Schwardt Oliver |
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
|
| Seager Nathan |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Sichau Jannik |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Simberg Dmitri |
Complement Alternative Pathway Inhibitors for Hemocompatibility of Nanoparticles in Multiple Animal Species.
|
| Skurnik Mikael |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Smiesko Martin |
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Sobała Łukasz |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Spirig Rolf |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Steel David |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Stravalaci Matteo |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Subramaniam and collaborators Shankar |
A spatial and tissue digital landscape of triple negative breast cancer and complement pathways
|
| Świerzko Anna |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Szamosi Johan |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Tenner Andrea |
Knowing the Enemy: Selectively targeting complement to treat Alzheimer disease and related dementias
|
| Theisen Erin |
Granzyme K Activates the Entire Complement Cascade
|
| Thielens Nicole |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Thomas Julie |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Thurman Joshua |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Toso Marc |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Traggiai Elisabetta |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Trombetta Elena |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Tsai Cheng-Chang |
Serum complement internalization is needed for UV-mediated nuclear bubbling cell death
|
| Van De Kar Nicole |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| van de Logt Anne-Els |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Van de Sompel Ariella |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Van de Walle Inge |
The story of empasiprubart (ARGX-117), a long acting inhibitory C2 antibody, from bench to MMN patients
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Van Slambrouck Jan |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Vanaudenaerde Bart |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Vermeire Severine |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Verstockt Bram |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Veuskens Bert |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Viatore Marika |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Vivarelli Marina |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Vos Robin |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Walker Patrick |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Wallace Dean |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Wang Zhongshen |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Whitfield Phil |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Widmer Kevin |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Williams Brandi |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Woodruff Trent |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Wu Wei |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Xiao Junyu |
Structural insights into IgM and complement activation
|
| Xie Long |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Zanella Gaia |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Zanoni Francesca |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Zecher Daniel |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Zelek Wioleta |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
Targeting complement in brain diseases.
|
| Zouace Moussa |
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Zouache Moussa |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
